In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative ...

The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of reciprocal tariffs later this week.

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk adults aged 50-59 this week. Read more here.

Shareholders have already approved a pay increase for British American Tobacco chief executive Tadeu Marroco. He could receive up to $24.1 million if the company boosts its profitability and if its ...

The Goldman Sachs Equal Weight U.S. Large Cap Equity ... Looking at individual holdings, Moderna Inc (MRNA) accounts for about 0.22% of total assets, followed by Entegris Inc (ENTG) and Dollar ...

Goldman Sachs said Monday that GSK (NYSE ... in our view.” While Moderna (MRNA) has an FDA-approved RSV vaccine, its messenger-RNA-based shot is only approved by the FDA for those aged 60 ...

The major U.S. equity indexes were lower midday Monday, as the Trump administration showed no signs of pulling back from ...

In response to growing tariff uncertainties, Goldman Sachs has raised its U.S. recession ... signaling heightened investor anxiety. Daily Moderna Inc. In the pharmaceutical space, Moderna ...

US stocks saw choppy trading on Tuesday (April 15) as investors digested a new round of first-quarter earnings reports and ...